Financial intelligence for Asia's healthcare markets
 
 
Remember me:

EXCLUSIVE: Qualitas to push button on IPO next week

Malaysian-based primary healthcare provider Qualitas Medical Group is due to push the button on its S$150 million (US$114 million) IPO in Singapore next week. It will be the first mainboard healthcare listing since IHH Healthcare floated in Kuala Lumpur and Singapore in July 2012.

Backed by Singaporean private equity firm Southern Capital Group, global coordinators are CIMB and Credit Suisse with DBS and Daiwa as bookrunners.

Investors are expected to jump at the deal which will see around 25% of the group floated. Although no cornerstone investors have been signed up, it is significant that Southern Capital is not selling down any of its 78% stake, which post IPO will be around 55%.

A successful IPO from Qualitas will be a shot in the arm for the SGX. In recent months a number of healthcare companies have looked at other exchanges. In late February primary healthcare services provider Republic Healthcare said that it planned to IPO on Hong Kong’s junior GEM board while HKE Holdings, a Singapore-based contractor specialising in the medical and healthcare sectors, said it was looking at the same board in September last year.

Not that the SGX is as subdued as some critics would have you believe. Healthcare services group Clearbridge Health raised S$24.6 million in its IPO on the Catalist, SGX’s junior board, in late December. It sold 88 million shares, or 18.3% of its enlarged share capital, at S$0.28 per share. Its shares have performed well and were last seen at S$0.54. In the wings too is Luye Medical Group, the regional healthcare services arm of Luye Life Sciences Group. At the start of March it mandated Bank of America Merrill Lynch, Credit Suisse and UBS for its up-to S$500 million SGX IPO.

But Qualitas is very focused on Singapore and an SGX listing makes sense for the group. It is not raising a massive amount, valuations for healthcare companies in Singapore are healthy and that is where growth for the company is likely to come from. Although the group is looking for acquisitions across the region, a significant proportion of proceeds will be used to buy clinics in Singapore.

Although it is too early to talk about an indicative range, bankers are looking to IHH and Health Management International – both based in Malaysia – as well as Singapore businesses like Q&M Dental and Singapore Medical Group, for comps.

This is Qualitas’ second attempt at a float. Although pricing had been set on the deal and cornerstone investors had been signed up, it pulled an IPO in the autumn of 2015. Chairman and managing director Noorul Ameen Mohamed Ishack said that the decision had been taken thanks to unfavourable market conditions, though those away from the deal said that the water had been muddied as CIMB and Credit Suisse were looking after the IPO while a parallel private sale was also explored by via Rothschild. Investors were said to be confused by mixed messages.

Founded in 1997, Qualitas Medical  operates a network of clinics in Malaysia with medical centres in Singapore, India, and Australia. It was listed on Singapore’s Catalist board in 2008. It was taken private in 2011 for US$36 million.

Bookbuilding is expected to begin next week with a listing planned for mid April.

Posted on: 23/03/2018 UTC+08:00


News

A 29-year-old doctor in Wuhan has become the latest victim of the coronavirus as worldwide panic about the pandemic continues to grow, The Guardian has reported.
Healthcare company Oue Lippo Healthcare has announced a profit of S$3.2 million ($2.3 million) for 2019, which compares to a loss of S$9.3 million reported for 2018.
Beijing-based China Jo-Jo Drugstores has reported a small net profit of $456,000 for the third quarter of its 2020 fiscal year, ending 31 December 2019, compared to a net loss of $2.2 million reported for Q3 2109.
The head of a leading hospital in Wuhan, the epicentre of a coronavirus outbreak, has died of the disease, according to China’s state television.
New Delhi-based Hempstreet, a research-to-retail healthcare start-up that focuses on cannabis uses in Ayurvedic medicine, has raised $1 million in pre-series A funding.
Sydney-based George Clinical, a global clinical research organisation, has appointed James as chief executive, replacing Glenn Kerkhof who becomes chairman.
Thomson Medical Group’s pre-tax profit for 2019 was $14.7 million, down 33% from the $22 million reported for 2018.
Ping An Healthcare and Technology Company has announced a 2019 loss of ¥746.7 million ($107.1 million), which compares to a net loss of ¥913.1 million announced for 2018.



Analysis

L.E.K. Consulting’s Fabio La Mola tells HealthInvestor Asia about a healthcare market going through major changes – creating significant opportunities for investors in the region.
Edwin Tong, senior minister for health, explains how the Ministry of Health in Singapore is supporting the growth in the number of seniors with Alzheimer's.
Penny Wan, regional vice-president and general manager, Japan and APAC, Amgen, writes about the public health challenge of cardiovascular diseases.
French-based international ophthalmic optics company Essilor has signed Letters of Intent with the Royal Government of Bhutan and the Central Monastic Body to strengthen the country’s vision care infrastructure.
April Chang, country manager at Cigna Singapore, argues that wellness programmes at work can lead to reduced absenteeism, higher productivity and increased morale among employees.
Steven Fang understands how to set up a healthcare company. Not only is he chief executive and founder of ASX-listed oncology company Invitrocue, he was also the founder of Singapore-based Cordlife Group, a healthcare company which provides cord blood and cord lining banking services.
Imagine a world in which you can consult with your doctor via video. She asks for a blood sample, which can be collected and analysed from a device in your home. After that is diagnosed, the prescription is automatically sent to the pharmacy and Uber then picks it up. The time from diagnosis to drugs at your home is only 60 minutes.
The digitisation of health data through blockchain technology is a groundbreaking solution that will empower patients and provide them with better access to healthcare.


Podcasts

HealthInvestor Asia twitter feed